Online Only Articles

LJ000328, a novel ALK2/3 kinase inhibitor, represses hepcidin and significantly improves the phenotype of IRIDA

IRSD, Université de Toulouse, INSERM, INRA, ENVT, UPS, Toulouse, France
IRSD, Université de Toulouse, INSERM, INRA, ENVT, UPS, Toulouse, France
IRSD, Université de Toulouse, INSERM, INRA, ENVT, UPS, Toulouse, France
IRSD, Université de Toulouse, INSERM, INRA, ENVT, UPS, Toulouse, France
IRSD, Université de Toulouse, INSERM, INRA, ENVT, UPS, Toulouse, France
IRSD, Université de Toulouse, INSERM, INRA, ENVT, UPS, Toulouse, France
Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, USA
La Jolla Pharmaceutical Company, San Diego, CA, USA
IRSD, Université de Toulouse, INSERM, INRA, ENVT, UPS, Toulouse, France
IRSD, Université de Toulouse, INSERM, INRA, ENVT, UPS, Toulouse, France
La Jolla Pharmaceutical Company, San Diego, CA, USA
Division of Cardiovascular Medicine, University of Maryland School of Medicine, Baltimore, USA
IRSD, Université de Toulouse, INSERM, INRA, ENVT, UPS, Toulouse, France
Vol. 105 No. 8 (2020): August, 2020 https://doi.org/10.3324/haematol.2019.236133